RISK OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS WITH NOVEL DRUGS APPROVED BY THE US FDA IN 2022: A DETAILED REVIEW OF DDI DATA FROM NDA DOCUMENTATION

被引：0
|
作者：
Yu, Jingjing [1 ]
Wang, Yan [1 ]
Ragueneau-Majlessi, Isabelle [1 ]
机构：
[1] Certara, Princeton, NJ USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2024年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P69
引用
收藏
页数：2
相关论文
共 34 条
  • [21] Prediction of inhibition-based drug-drug interactions using aurscope ADME/DDI® knowledge base from in vitro and in vivo data.: Case study on FDA recommended in vivo probe substrates
    Barberan, Olivier
    Ijjaali, Ismail
    Dubus, Eludie
    Petitet, François
    Michel, André
    DRUG METABOLISM REVIEWS, 2006, 38 : 79 - 80
  • [22] Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
    Plasencia-Garcia, Beatriz Oda
    Rodriguez-Menendez, Gonzalo
    Rico-Rangel, Maria Isabel
    Rubio-Garcia, Ana
    Torello-Iserte, Jaime
    Crespo-Facorro, Benedicto
    PSYCHOPHARMACOLOGY, 2021, 238 (02) : 329 - 340
  • [23] Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
    Beatriz Oda Plasencia-García
    Gonzalo Rodríguez-Menéndez
    María Isabel Rico-Rangel
    Ana Rubio-García
    Jaime Torelló-Iserte
    Benedicto Crespo-Facorro
    Psychopharmacology, 2021, 238 : 329 - 340
  • [24] An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the US Food and Drug Administration, 2012-2022
    Collins, Grace
    McKelvey, Brittany
    Andrews, Hillary S.
    Allen, Jeff D.
    Stewart, Mark D.
    CLINICAL CANCER RESEARCH, 2024, 30 (05) : 937 - 941
  • [25] A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions
    Evans, Alison
    Roy, Debabrata
    Dhanda, Sandeep
    Lane, Samantha
    Coutinho, Graca
    Kulasekaran, Anuradha
    Miller-Shakesby, David
    Ramamoorthi, Nagalakshmi
    Shakir, Saad
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Findings on In Vitro Transporter-Mediated Drug Interactions and Their Follow-Up Actions for Labeling: Analysis of Drugs Approved by US FDA between 2017 and 2021
    Lee, Kyeong-Ryoon
    Chang, Ji-Eun
    Yoon, Jongmin
    Jin, Hyojeong
    Chae, Yoon-Jee
    PHARMACEUTICS, 2022, 14 (10)
  • [27] Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs
    Mochizuki, Tatsuki
    Aoki, Yasunori
    Yoshikado, Takashi
    Yoshida, Kenta
    Lai, Yurong
    Hirabayashi, Hideki
    Yamaura, Yoshiyuki
    Rockich, Kevin
    Taskar, Kunal
    Takashima, Tadayuki
    Chu, Xiaoyan
    Zamek-Gliszczynski, Maciej J.
    Mao, Jialin
    Maeda, Kazuya
    Furihata, Kenichi
    Sugiyama, Yuichi
    Kusuhara, Hiroyuki
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (06): : 1519 - 1531
  • [28] Nonsteroidal Anti-inflammatory Drugs Utilization Patterns and Risk of Adverse Events due to Drug-Drug Interactions among Elderly Patients: A Study from Jordan
    Al-Azayzih, Ahmad
    Al-Azzam, Sayer, I
    Alzoubi, Karem H.
    Jarab, Anan S.
    Kharaba, Zelal
    Al-Rifai, Rami H.
    Alnajjar, Munther S.
    SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (04) : 504 - 508
  • [29] Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022
    Olivier, Timothee
    Smith, Claire E. P.
    Haslam, Alyson
    Addeo, Alfredo
    Prasad, Vinay
    JOURNAL OF CANCER POLICY, 2023, 37
  • [30] Laboratory Tests in the Clinical Risk Management of Potential Drug-Drug Interactions A Cross-Sectional Study Using Drug-Dispensing Data from 100 Dutch Community Pharmacies
    Geerts, Arjen F. J.
    De Koning, Fred H. P.
    De Smet, Peter A. G. M.
    Van Solinge, Wouter W.
    Egberts, Toine C. G.
    DRUG SAFETY, 2009, 32 (12) : 1189 - 1197
1234